Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from SDAI ( (SG:5TI) ) is now available.
SDAI Limited has secured shareholder approval to diversify its core business into biotechnology, cementing a pivot toward anti-ageing and longevity-focused healthcare products and services. Management sees this move as a way to tap the rapidly expanding global anti-ageing market, align with Singapore’s RIE2030 innovation agenda and build a defensible niche in biological age management tailored to Asian consumers.
The group has already rolled out key initiatives, including the Bluecode Biotech B-III skincare line in China and Singapore, a research partnership with longevity specialist LiveBeyond, and a joint venture with Hubei Qiai to expand mugwort-based moxibustion offerings across ASEAN. These steps are intended to create new revenue streams, diversify geographically and position SDAI as an early mover in Asia’s longevity sector, though the company cautions that the financial impact will materialise gradually.
More about SDAI
SDAI Limited, listed on the Catalist Board of the Singapore Exchange, is undergoing a strategic transformation into a biotechnology company focused on healthcare-related products and services. Its portfolio spans advanced plant stem cell-based skincare under the Bluecode Biotech B-III brand and efforts to globalise traditional Chinese moxibustion, targeting Asia’s fast-growing anti-ageing and longevity markets.
Current Market Cap: S$33.97M
For detailed information about 5TI stock, go to TipRanks’ Stock Analysis page.